SHCM
GILD icon

Stokes & Hubbell Capital Management’s Gilead Sciences GILD Stock Holding History

Stokes & Hubbell Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2,706
Closed -$226K – 87
2016
Q2 		$226K Sell
2,706
-311
-10% -$27.6K 0.1% 80
2016
Q1 		$277K Buy
3,017
+409
+16% +$36.9K 0.13% 72
2015
Q4 		$264K Sell
2,608
-296
-10% -$30.8K 0.14% 71
2015
Q3 		$285K Buy
+2,904
New +$323K 0.17% 63

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Stokes & Hubbell Capital Management's GILD Position: Q3 2016 in Review

Stokes & Hubbell Capital Management sold out of Gilead Sciences (GILD) in Q3 2016, closing a stake of 2,706 shares — an estimated $226K sold.

Stokes & Hubbell Capital Management first reported a position in GILD in Q3 2015 and held it in 4 quarters. The position peaked at $285K in Q3 2015. 1,561 funds tracked by Wall St. Rank hold GILD as of Q3 2016.

  • Stokes & Hubbell Capital Management reported no remaining Gilead Sciences position as of Q3 2016 after selling out during the quarter.
  • Stokes & Hubbell Capital Management sold 2,706 Gilead Sciences shares in Q3 2016, an estimated $226K.
  • Stokes & Hubbell Capital Management first reported a position in Gilead Sciences in Q3 2015 and held it in 4 quarters.
  • Stokes & Hubbell Capital Management's Gilead Sciences position peaked at $285K in Q3 2015.
  • 1,561 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2016.

Based on Stokes & Hubbell Capital Management's 13F filing for Q3 2016, filed 7 Oct 2016.